0001639691-20-000014.txt : 20200226 0001639691-20-000014.hdr.sgml : 20200226 20200226060513 ACCESSION NUMBER: 0001639691-20-000014 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20200226 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200226 DATE AS OF CHANGE: 20200226 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LivaNova PLC CENTRAL INDEX KEY: 0001639691 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 981268150 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37599 FILM NUMBER: 20653221 BUSINESS ADDRESS: STREET 1: 20 EASTBOURNE TERRACE CITY: LONDON STATE: X0 ZIP: W2 6LG BUSINESS PHONE: 4402033250662 MAIL ADDRESS: STREET 1: 20 EASTBOURNE TERRACE CITY: LONDON STATE: X0 ZIP: W2 6LG FORMER COMPANY: FORMER CONFORMED NAME: Sand Holdco Plc DATE OF NAME CHANGE: 20150420 FORMER COMPANY: FORMER CONFORMED NAME: Sand Holdco Ltd DATE OF NAME CHANGE: 20150415 8-K 1 livanovaform8-k4q19ear.htm 8-K Document
false0001639691LIVANOVA PLC 0001639691 2020-02-26 2020-02-26
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 26, 2020

livanova8ktemplat_imagea02.jpg
LivaNova PLC
(Exact Name of Registrant as Specified in its Charter)
England and Wales
 
001-37599
 
98-1268150
(State or Other Jurisdiction
 of Incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)

20 Eastbourne Terrace
London, W2 6LG
United Kingdom
(Address of Principal Executive Offices)

+44 20 33250660
(Registrant’s Telephone Number, Including Area Code)

N/A
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name on each exchange on which registered
Ordinary Shares - £1.00 par value per share
LIVN
NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company
☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
 
 
☐


Item 2.02 Results of Operations and Financial Condition.

On February 26, 2020, LivaNova PLC (the “Company”) issued a press release announcing financial results for full-year ended December 31, 2019. The Company will host a business update conference call and webcast today, February 26, 2020, at 1 p.m. London time (8 a.m. Eastern Time), during which the Company will discuss the financial results. The conference call will be available to interested parties through a live audio webcast and accessible through the Investor Relations section of the LivaNova corporate website at www.livanova.com. A copy of the Company’s press release is furnished as Exhibit 99.1 on this Current Report on Form 8-K.

The information in Item 2.02 of this report is being furnished, not filed, for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and pursuant to General Instruction B.2 of Form 8-K, will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference.


Item 9.01 Financial Statements and Exhibits

(d)    Exhibits.



2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
LivaNova PLC
 
 
 
 
Date: February 26, 2020
By:/s/ Keyna Skeffington          
 
Name: Keyna Skeffington
 
Title: Sr. Vice President & General Counsel
 
 


3
 EX-99.1 2 ex9914q19earningspress.htm LIVANOVA PRESS RELEASE DATED FEBRUARY 26, 2020 Exhibit


EXHIBIT 99.1
download.jpg          NEWS RELEASE

LivaNova Reports Fourth Quarter and
Full-Year 2019 Results

London, February 26, 2020 – LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full-year ended December 31, 2019.

For the fourth quarter of 2019, worldwide sales were $287.6 million, a decrease of 3.2 percent on a reported basis and a decrease of 2.2 percent on a constant-currency basis, as compared to the same quarter of the previous year. On the basis of U.S. Generally Accepted Accounting Principles (GAAP), fourth quarter 2019 diluted loss per share from continuing operations was $2.96. Fourth quarter 2019 adjusted diluted earnings per share from continuing operations were $1.00. For full-year 2019, worldwide sales from continuing operations were $1.1 billion, a decrease of 2.1 percent on a reported basis and an increase of 0.1 percent on a constant-currency basis, as compared to the previous year. On a GAAP basis, full-year 2019 diluted loss per share from continuing operations was $3.22. Full-year 2019 adjusted diluted earnings per share from continuing operations were $3.08.

“We are encouraged by several trends in our fourth quarter 2019 results, highlighted by strong sales in Advanced Circulatory Support (ACS) and continued stability in our Epilepsy business. These successes were offset by an unexpected component supplier issue for oxygenators and execution challenges in the Rest of World region relating to distribution model changes," said Damien McDonald, Chief Executive Officer of LivaNova. “Our team is focused, and I am confident that the building blocks we have put in place in 2019 will enable us to achieve our financial and operational goals in 2020.”

Fourth Quarter 2019 Results
The following table highlights worldwide sales for the fourth quarter of 2019 and by business:


1


$ in millions
Three months ended December 31,
As Reported % Change
Constant- Currency
% Change
Business / Product Line:
2019
2018
Cardiopulmonary

$132.6


$146.7

(9.6
%)
(8.4
%)
Heart Valves
32.1

28.6

12.4
%
14.0
%
Advanced Circulatory Support
8.8

7.4

19.7
%
19.8
%
Cardiovascular
173.5

182.6

(5.0
%)
(3.8
%)
Neuromodulation
113.1

113.6

(0.4
%)
0.1
%
Other
1.0

0.8

27.9
%
31.3
%
Total Net Sales
$287.6
$297.0
(3.2
%)
(2.2
%)

•
Note: Numbers may not add up precisely due to rounding. Constant-currency percent change is considered a non-GAAP metric.

All sales growth rates below reflect comparable, constant-currency growth. Constant-currency growth accounts for the impact from fluctuations in the various currencies in which the Company operates as compared to reported growth.

Cardiovascular
Cardiovascular sales, which include cardiopulmonary products, heart valves and ACS, were $173.5 million, representing a 3.8 percent decrease versus the fourth quarter of 2018.

Sales in cardiopulmonary products were $132.6 million, representing an 8.4 percent decrease versus the fourth quarter of 2018. This business was negatively impacted by exiting a Canadian distribution agreement in the Rest of World region, which equated to $8.7 million in the prior-year period and the component supplier issue related to the Inspire® oxygenator.

Heart valve sales, including tissue and mechanical heart valves, were $32.1 million, an increase of 14.0 percent compared to the fourth quarter of 2018.

ACS sales were $8.8 million in the quarter, an increase of 19.8 percent compared to the fourth quarter of 2018, primarily related to growth in ProtekDuo® and TandemHeart® kits.


2


Neuromodulation
Neuromodulation sales were $113.1 million in the fourth quarter, representing a 0.1 percent increase versus the fourth quarter of 2018. The Europe and Rest of World regions both delivered another quarter of double-digit growth.

Financial Performance
On a GAAP basis, fourth quarter 2019 operating loss from continuing operations was $144.0 million, which includes charges of $100.4 million for the net impact of the shutdown related to the discontinuation of the Transcatheter Mitral Valve program and $33.2 million for litigation involving the Company's 3T Heater-Cooler device. Adjusted operating income from continuing operations for the fourth quarter of 2019 was $55.3 million, a decrease of 18.4 percent as compared to the fourth quarter of 2018. This was primarily driven by performance in Neuromodulation, expected investments in the Rest of World region to support commercial capabilities and R&D for Strategic Portfolio Initiatives, offset somewhat by improvements in gross profit.

Fourth quarter 2019 adjusted diluted earnings per share from continuing operations were $1.00, a decrease of 10.7 percent as compared to the fourth quarter of 2018.

Full-Year 2019 Results
Worldwide sales for full-year 2019 were $1.1 billion, up 0.1 percent on a constant-currency basis compared to full-year 2018. The following table highlights worldwide sales for full-year 2019 and by business:
$ in millions
Twelve months ended December 31,
As Reported % Change
Constant- Currency
% Change
Business / Product Line:
2019
2018
Cardiopulmonary

$504.7


$536.4

(5.9
%)
(3.1
%)
Heart Valves
120.0

126.0

(4.7
%)
(0.7
%)
Advanced Circulatory Support
31.9

19.5

64.0
%
64.1
%
Cardiovascular
656.6

681.8

(3.7
%)
(0.7
%)
Neuromodulation
424.5

423.0

0.4
%
1.2
%
Other
3.0

2.1

38.7
%
46.0
%
Total Net Sales
$1,084.2
$1,107.0
(2.1
%)
0.1
%

•
Numbers may not add up precisely due to rounding. Constant-currency percent change is considered a non-GAAP metric.

All sales growth rates below reflect comparable, constant-currency growth. Constant-currency growth accounts for the impact from fluctuations in the various currencies in which the Company operates as compared to reported growth.

3



Cardiovascular
Cardiovascular sales were $656.6 million, representing a 0.7 percent decrease versus full-year 2018.

Sales in cardiopulmonary products were $504.7 million, representing a 3.1 percent decrease versus full-year 2018. This was due to the impact of exiting a Canadian distribution agreement in the Rest of World region, which equated to $32.9 million in the prior-year period and the component supplier issue related to the Inspire oxygenator.

Heart valve sales, including tissue and mechanical heart valves, were $120.0 million, a decrease of 0.7 percent compared to full-year 2018.

ACS sales were $31.9 million, an increase of 64.1 percent compared to 2018, primarily related to growth in ProtekDuo and one additional quarter of sales in 2019 versus 2018 since TandemLife was acquired in April of 2018.

Neuromodulation
Neuromodulation sales were $424.5 million for full-year 2019, representing a 1.2 percent increase compared to full-year 2018. Sales were driven by adoption of the SenTiva® VNS Therapy® System and very strong growth in the Europe and Rest of World regions.

Financial Performance
On a GAAP basis, full-year 2019 operating loss from continuing operations was $168.9 million. Adjusted operating income from continuing operations for the full-year 2019 was $179.7 million, a decrease of 16.9 percent as compared to full-year 2018, primarily impacted by performance in Neuromodulation, investments in R&D to support Strategic Portfolio Initiatives, commercial investments in ACS and the Rest of World region, offset somewhat by favorable product mix and gross margin improvements.

2020 Guidance
LivaNova expects worldwide net sales from continuing operations for full-year 2020 to grow between 3 and 5 percent on a constant-currency basis. Adjusted diluted earnings per share from continuing operations for 2020 are expected to be in the range of $3.10 to $3.30.


4


In 2020, the Company estimates that adjusted cash flow from operations, excluding litigation payments, will be in the range of $180 to $200 million. Capital expenditures are projected to range between $25 to $35 million.

"We are entering 2020 with a strategy focused on delivering higher sales growth, expanding gross margins and improving cash generation,” said McDonald. “We are investing in research and development to advance our pipeline and accomplish several important milestones for patients with Difficult-to-Treat Depression, Heart Failure and Obstructive Sleep Apnea.”

Webcast and Conference Call Instructions
The Company will host a live audio webcast for interested parties commencing at 1 p.m. London time (8 a.m. Eastern Time) on Wednesday, February 26 that will be accessible through the Investor Relations section of the LivaNova website at www.livanova.com. To listen to the conference call live by telephone, dial 877-272-0401 (if dialing from within the U.S.) or 706-902-4062 (if dialing from outside the U.S.). The conference ID is 6456945.

Within 24 hours of the webcast, a replay will be available under the "News & Events / Presentations" section of the Investor Relations portion of the LivaNova website, where it will be archived and accessible for approximately 12 months.

About LivaNova
LivaNova PLC is a global medical technology and innovation company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through innovative medical technologies, delivering life-changing improvements for both the Head and Heart. Headquartered in London, LivaNova employs approximately 4,000 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide. LivaNova operates as two businesses: Cardiovascular and Neuromodulation, with operating headquarters in Mirandola (Italy) and Houston (U.S.), respectively.
For more information, please visit www.livanova.com.


5


Use of Non-GAAP Financial Measures
In this press release, management has disclosed financial measurements that present financial information not necessarily in accordance with GAAP. Company management uses these measurements aids in monitoring the Company’s ongoing financial performance from quarter to quarter and year to year on a regular basis and for benchmarking against other medical technology companies. Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. These non-GAAP financial measures should be considered along with, but not as alternatives to, the operating performance measure as prescribed by GAAP.
Unless otherwise noted, all sales growth rates in this release reflect comparable, constant-currency growth. Management believes that referring to comparable, constant-currency growth is the most useful way to evaluate the sales performance of LivaNova and to compare the sales performance of current periods to prior periods on a consistent basis. Constant-currency growth, a non-GAAP financial measure, measures the change in sales between current and prior-year periods using average exchange rates in effect during the applicable prior-year period.
LivaNova calculates forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For example, forward-looking net sales growth projections are estimated on a constant-currency basis and exclude the impact of foreign currency fluctuations. Forward-looking non-GAAP adjusted tax rate and adjusted diluted earnings per share guidance exclude other items such as, but not limited to, changes in fair value of contingent consideration arrangements, asset impairment charges and product remediation costs that would be included in comparable GAAP financial measures. The most directly comparable GAAP measure for constant-currency net sales, non-GAAP adjusted tax rate and adjusted diluted earnings per share are net sales, the effective tax rate, and earnings per share, respectively. However, non-GAAP financial adjustments on a forward-looking basis are subject to uncertainty and variability as they are dependent on many factors, including but not limited to, the effect of foreign currency exchange fluctuations, impacts from potential acquisitions or divestitures, gains or losses on the potential sale of businesses or other assets, restructuring costs, merger and integration activities, changes in fair value of contingent consideration arrangements, product remediation costs, asset impairment charges, and the tax impact of the items above and the tax impact of tax law changes or other tax matters. Accordingly, reconciliations to the most directly comparable forward-looking GAAP financial measures are not available without unreasonable effort.

The Company also believes adjusted financial measures such as adjusted gross profit; adjusted selling, general and administrative expense; adjusted research and development expense; adjusted other operating expenses; adjusted operating income from continued operations; adjusted income tax expense; adjusted net income from

6


continuing operations; and adjusted diluted earnings per share, are measures by which LivaNova generally uses to facilitate management review of the operational performance of the company, to serve as a basis for strategic planning, and to assist in the design of compensation incentive plans. Furthermore, adjusted financial measures allow investors to evaluate the Company’s core performance for different periods on a more comparable and consistent basis, and with other entities in the medical technology industry by adjusting for items that are not related to the ongoing operations of the Company or incurred in the ordinary course of business.

Safe Harbor Statement
Certain statements in this press release, other than purely historical information, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, LivaNova’s plans, objectives, strategies, financial performance and outlook, trends, the amount and timing of future cash distributions, prospects or future events and involve known and unknown risks that are difficult to predict. As a result, our actual financial results, performance, achievements or prospects may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” “believe,” “will,” “should,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “forecast,” “foresee,” or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based on estimates and assumptions that, while considered reasonable by LivaNova and its management based on their knowledge and understanding of the business and industry, are inherently uncertain. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements. Investors are cautioned that all such statements involve risks and uncertainties, including without limitation, statements concerning achieving a stronger future, driving sustainable growth and value to our shareholders, projected net sales, adjusted diluted earnings per share, cash flow from operations, capital expenditures, and depreciation and amortization for 2019, advancing our growth, driving product launches and funding our equity investments, executing on our targets and retaining our focus, energy and discipline as a company, filing our Form 10-K on a timely basis, remediating any known material weaknesses or deficiencies, serving the needs of our customers and patients, and delivering strong value to our shareholders. Important factors that may cause actual results to differ include, but are not limited to: (i) the inability of LivaNova to meet expectations regarding the timing, completion and accounting of tax treatments; (ii) organizational and governance structure; (iii) reductions in customer spending, a slowdown in customer payments and changes in customer demand for products and services; (iv) unanticipated changes relating to competitive factors in the industries in which LivaNova operates; (v) the ability to hire and retain key personnel; (vi) the ability

7


to attract new customers and retain existing customers in the manner anticipated; (vii) changes in legislation or governmental regulations affecting LivaNova; (viii) international, national or local economic, social or political conditions that could adversely affect LivaNova, its partners or its customers; (ix) conditions in the credit markets; (x) business and other financial risks inherent to the industries in which LivaNova operates; (xi) risks associated with settlement of litigation and assumptions made in connection with critical accounting estimates and legal proceedings; (xii) LivaNova’s international operations, which are subject to the risks of currency fluctuations and foreign exchange controls; (xiii) and the potential for international unrest, economic downturn or effects of currencies, tax assessments, tax adjustments, anticipated tax rates, raw material costs or availability, benefit or retirement plan costs, or other regulatory compliance costs. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company’s business, including those described in the “Risk Factors” section of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents filed from time to time with the United States Securities and Exchange Commission by LivaNova.
We caution you not to place undue reliance on any forward-looking statements, which are made only as of the date of this press release. The Company does not undertake or assume any obligation to update publicly any of the forward-looking statements in this press release to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
Melissa Farina
Vice President, Investor Relations
Phone: +1 (281) 228 7262
e-mail: investorrelations@LivaNova.com

8


LIVANOVA PLC
NET SALES
(U.S. dollars in millions)
 
 
 
Three Months Ended December 31,
 
 
 
2019
 
2018
 
% Change at Actual Currency Rates
 
% Change at Constant-Currency Rates (1)
Cardiopulmonary
 
 
 
 
 
 
 
 
US
 

$41.9

 

$40.2

 
4.3
%
 
4.3
%
Europe
 
35.7

 
36.7

 
(2.9
%)
 
(0.2
%)
Rest of World
 
55.0

 
69.8

 
(21.3
%)
 
(20.1
%)
Total
 
132.6

 
146.7

 
(9.6
%)
 
(8.4
%)
Heart Valves
 
 
 
 
 
 
 
 
US
 
5.2

 
5.9

 
(10.9
%)
 
(10.9
%)
Europe
 
9.8

 
10.9

 
(9.8
%)
 
(7.4
%)
Rest of World
 
17.1

 
11.8

 
44.4
%
 
46.0
%
Total
 
32.1

 
28.6

 
12.4
%
 
14.0
%
Advanced Circulatory Support
 
 
 
 
 
 
 
 
US
 
8.5

 
7.2

 
18.4
%
 
18.4
%
Europe
 
0.2

 
0.2

 
N/A

 
N/A

Rest of World
 
0.1

 
—

 
N/A

 
N/A

Total
 
8.8

 
7.4

 
19.7
%
 
19.8
%
Cardiovascular
 
 
 
 
 
 
 
 
US
 
55.6

 
53.2

 
4.5
%
 
4.5
%
Europe
 
45.7

 
47.8

 
(4.3
%)
 
(1.7
%)
Rest of World
 
72.1

 
81.6

 
(11.6
%)
 
(10.4
%)
Total
 
173.5

 
182.6

 
(5.0
%)
 
(3.8
%)
Neuromodulation
 
 
 
 
 
 
 
 
US
 
89.5

 
94.4

 
(5.2
%)
 
(5.2
%)
Europe
 
12.2

 
10.7

 
13.7
%
 
16.6
%
Rest of World
 
11.4

 
8.4

 
35.6
%
 
39.4
%
Total
 
113.1

 
113.6

 
(0.4
%)
 
0.1
%
Other
 
 
 
 
 
 
 
 
US
 
—

 
—

 
N/A

 
N/A

Europe
 
—

 
—

 
N/A

 
N/A

Rest of World
 
1.0

 
0.8

 
27.9
%
 
31.3
%
Total
 
1.0

 
0.8

 
27.9
%
 
31.3
%
Totals
 
 
 
 
 
 
 
 
US
 
145.1

 
147.6

 
(1.7
%)
 
(1.7
%)
Europe
 
57.9

 
58.5

 
(1.0
%)
 
1.6
%
Rest of World
 
84.6

 
90.9

 
(6.9
%)
 
(5.4
%)
Total
 

$287.6

 

$297.0

 
(3.2
%)
 
(2.2
%)
 
 
 
 
 
 
 
 
 
 
(1)
Constant-currency growth, a non-GAAP financial measure, measures the change in sales between current and prior-year periods using average exchange rates in effect during the applicable prior-year period.
*
The sales results presented are unaudited. Numbers may not add up precisely due to rounding.


9


LIVANOVA PLC
NET SALES
(U.S. dollars in millions)
 
 
 
Twelve Months Ended December 31,
 
 
 
2019
 
2018
 
% Change at Actual Currency Rates
 
% Change at Constant-Currency Rates (1)
Cardiopulmonary
 
 
 
 
 
 
 
 
US
 
$161.5

 

$161.1

 
0.2
%
 
0.2
%
Europe
 
135.6

 
141.7

 
(4.3
%)
 
0.9
%
Rest of World
 
207.6

 
233.6

 
(11.1
%)
 
(7.8
%)
Total
 
504.7

 
536.4

 
(5.9
%)
 
(3.1
%)
Heart Valves
 
 
 
 
 
 
 
 
US
 
18.9

 
24.7

 
(23.5
%)
 
(23.5
%)
Europe
 
40.5

 
44.3

 
(8.4
%)
 
(3.4
%)
Rest of World
 
60.6

 
57.0

 
6.3
%
 
11.3
%
Total
 
120.0

 
126.0

 
(4.7
%)
 
(0.7
%)
Advanced Circulatory Support
 
 
 
 
 
 
 
 
US
 
30.8

 
18.6

 
65.6
%
 
65.6
%
Europe
 
0.7

 
0.6

 
N/A

 
N/A

Rest of World
 
0.4

 
0.3

 
N/A

 
N/A

Total
 
31.9

 
19.5

 
64.0
%
 
64.1
%
Cardiovascular
 
 
 
 
 
 
 
 
US
 
211.2

 
204.4

 
3.3
%
 
3.3
%
Europe
 
176.9

 
186.6

 
(5.2
%)
 
—
%
Rest of World
 
268.6

 
290.8

 
(7.7
%)
 
(4.0
%)
Total
 
656.6

 
681.8

 
(3.7
%)
 
(0.7
%)
Neuromodulation
 
 
 
 
 
 
 
 
US
 
335.3

 
349.0

 
(3.9
%)
 
(3.9
%)
Europe
 
46.3

 
42.4

 
9.0
%
 
15.0
%
Rest of World
 
43.0

 
31.6

 
36.1
%
 
39.7
%
Total
 
424.5

 
423.0

 
0.4
%
 
1.2
%
Other
 
 
 
 
 
 
 
 
US
 
—

 
—

 
N/A

 
N/A

Europe
 
—

 
—

 
N/A

 
N/A

Rest of World
 
3.0

 
2.1

 
38.7
%
 
46.0
%
Total
 
3.0

 
2.1

 
38.7
%
 
46.0
%
Totals
 
 
 
 
 
 
 
 
US
 
546.5

 
553.4

 
(1.3
%)
 
(1.3
%)
Europe
 
223.2

 
229.0

 
(2.5
%)
 
2.8
%
Rest of World
 
314.5

 
324.5

 
(3.1
%)
 
0.5
%
Total
 

$1,084.2

 

$1,107.0

 
(2.1
%)
 
0.1
%
 
 
 
 
 
 
 
 
 
 
(1)
Constant-currency growth, a non-GAAP financial measure, measures the change in sales between current and prior-year periods using average exchange rates in effect during the applicable prior-year period.
*
The sales results presented are unaudited. Numbers may not add up precisely due to rounding.


10


LIVANOVA PLC AND SUBSIDIARIES
 
 
 
 
CONDENSED CONSOLIDATED STATEMENTS OF INCOME - UNAUDITED
 
 
(U.S. dollars in millions, except per share amounts)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Three Months Ended December 31,
 
 
 
 
 
2019
 
2018
 
% Change
Net sales
 

$287.6

 

$297.0

 
 
Costs and expenses:
 


 

 
 
 
Cost of sales - exclusive of amortization
 
78.3

 
90.9

 
 
 
Product remediation
 
4.6

 
2.0

 
 
 
Selling, general and administrative
 
130.6

 
122.2

 
 
 
Research and development
 
25.9

 
37.6

 
 
 
Merger and integration expenses
 
9.1

 
4.4

 
 
 
Restructuring expenses
 
7.7

 
13.1

 
 
 
Impairment of goodwill
 
42.4

 
—

 
 
 
Impairment of intangible assets
 
89.0

 
—

 
 
 
Amortization of intangibles
 
10.7

 
9.1

 
 
 
Litigation provision, net
 
33.2

 
294.0

 
 
Operating loss from continuing operations
 
(144.0
)
 
(276.5
)
 
(47.9
%)
 
Interest expense, net
 
(4.4
)
 
(2.1
)
 
 
 
Foreign exchange and other losses
 
(1.7
)
 
(0.8
)
 
 
Loss from continuing operations before tax
 
(150.1
)
 
(279.4
)
 
(46.3
%)
 
Income tax benefit
 
(6.7
)
 
(69.8
)
 
 
Net loss from continuing operations
 
(143.4
)
 
(209.5
)
 
(31.6
%)
Net income (loss) from discontinued operations, net of tax
 
0.2

 
(1.0
)
 
 
Net loss
 

($143.2
)
 

($210.6
)
 
(32.0
%)
 
 
 
 
 
 
 
 
Basic and diluted loss per share:
 
 
 
 
 
 
 
Continuing operations
 

($2.96
)
 

($4.32
)
 
 
 
Discontinued operations
 
—

 
(0.02
)
 
 
 
 
 

($2.96
)
 

($4.34
)
 
 
 
 
 
 
 
 
 
 
Weighted average common shares outstanding
 
 
 
 
 
 
 
Basic and diluted
 
48.4

 
48.5

 
 
 
 
 
 
 
 
 
 
*
Numbers may not add up precisely due to rounding.
 
 
 
 
 
 

11


Adjusted Financial Measures (U.S. dollars in millions, except per share amounts)
 
 
 
 
 
 
 
 
 
 
 
Three Months Ended December 31,
 
 
 
 
 
2019
 
2018
 
% Change (1)
Adjusted SG&A (1)
 

$107.5

 

$100.6

 
6.9
%
Adjusted R&D (1)
 
37.6

 
36.4

 
3.3
%
Adjusted operating income from continuing operations (1)
 
55.3

 
67.8

 
(18.4
%)
Adjusted income from continuing operations, net of tax (1)
 
48.8

 
55.2

 
(11.6
%)
Adjusted diluted earnings per share from continuing operations (1)
 

$1.00

 

$1.12

 
(10.7
%)
 
 
 
 
 
 
 
 
(1)
Adjusted financial measures are non-GAAP measures and exclude specified items as described and reconciled in the "Reconciliation of GAAP to non-GAAP Financial Measures" contained in the press release.

Statistics (as a % of net sales, except for income tax rate)
 
 
 
 
 
 
 
 
 
 
 
GAAP Three Months Ended December 31,
 
Adjusted (1) Three Months Ended December 31,
 
 
 
2019
 
2018
 
2019
 
2018
Gross profit
 
71.2
%
 
68.7
%
 
69.7
%
 
69.0
%
SG&A
 
45.4
%
 
41.2
%
 
37.4
%
 
33.9
%
R&D
 
9.0
%
 
12.7
%
 
13.1
%
 
12.2
%
Operating (loss) income from continuing operations
 
(50.1
%)
 
(93.1
%)
 
19.2
%
 
22.8
%
Net (loss) income from continuing operations, net of tax
 
(49.9
%)
 
(70.6
%)
 
17.0
%
 
18.6
%
Income tax rate
 
4.5
%
 
25.0
%
 
5.3
%
 
16.0
%
 
 
 
 
 
 
 
 
 
 
(1)
Adjusted financial measures are non-GAAP measures and exclude specified items as described and reconciled in the "Reconciliation of GAAP to non-GAAP Financial Measures" contained in the press release.


12


LIVANOVA PLC AND SUBSIDIARIES
 
 
 
 
CONDENSED CONSOLIDATED STATEMENTS OF INCOME - UNAUDITED
 
 
(U.S. dollars in millions, except per share amounts)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Twelve Months Ended December 31,
 
 
 
 
 
2019
 
2018
 
% Change
Net sales
 

$1,084.2

 

$1,107.0

 
 
Costs and expenses:
 
 
 
 
 
 
 
Cost of sales - exclusive of amortization
 
323.6

 
361.8

 
 
 
Product remediation
 
15.8

 
10.7

 
 
 
Selling, general and administrative
 
506.5

 
465.0

 
 
 
Research and development
 
149.9

 
146.0

 
 
 
Merger and integration expenses
 
23.5

 
24.4

 
 
 
Restructuring expenses
 
12.3

 
15.9

 
 
 
Impairment of goodwill
 
42.4

 
—

 
 
 
Impairment of intangible assets
 
139.3

 
—

 
 
 
Amortization of intangibles
 
40.4

 
37.2

 
 
 
Litigation provision, net
 
(0.6
)
 
294.0

 
 
Operating loss from continuing operations
 
(168.9
)
 
(248.1
)
 
(31.9
%)
 
Interest expense, net
 
(14.3
)
 
(9.0
)
 
 
 
Gain on acquisition
 
—

 
11.5

 
 
 
Foreign exchange and other losses
 
(2.5
)
 
(1.9
)
 
 
Loss from continuing operations before tax
 
(185.7
)
 
(247.4
)
 
(24.9
%)
 
Income tax benefit
 
(30.2
)
 
(69.6
)
 
 
 
Losses from equity method investments
 
—

 
(0.6
)
 
 
Net loss from continuing operations
 
(155.5
)
 
(178.5
)
 
(12.9
%)
Net income (loss) from discontinued operations, net of tax
 
0.4

 
(10.9
)
 
 
Net loss
 

($155.2
)
 

($189.4
)
 
(18.1
%)
 
 
 
 
 
 
 
 
Basic and diluted (loss) income per share:
 
 
 
 
 
 
 
Continuing operations
 

($3.22
)
 

($3.68
)
 
 
 
Discontinued operations
 
0.01

 
(0.23
)
 
 
 
 
 

($3.21
)
 

($3.91
)
 
 
 
 
 
 
 
 
 
 
Weighted average common shares outstanding
 
 
 
 
 
 
 
Basic and diluted
 
48.3

 
48.5

 
 
 
 
 
 
 
 
 
 
*
Numbers may not add up precisely due to rounding.
 
 
 
 
 
 

13


Adjusted Financial Measures (U.S. dollars in millions, except per share amounts)
 
 
 
 
 
 
 
 
 
 
 
Twelve Months Ended December 31,
 
 
 
 
 
2019
 
2018
 
% Change (1)
Adjusted SG&A (1)
 

$421.6

 

$402.5

 
4.7
%
Adjusted R&D (1)
 
152.9

 
135.7

 
12.7
%
Adjusted operating income from continuing operations (1)
 
179.7

 
216.2

 
(16.9
%)
Adjusted income from continuing operations, net of tax (1)
 
150.4

 
175.3

 
(14.2
%)
Adjusted diluted earnings per share from continuing operations (1)
 

$3.08

 

$3.55

 
(13.2
%)
 
 
 
 
 
 
 
 
(1)
Adjusted financial measures are non-GAAP measures and exclude specified items as described and reconciled in the "Reconciliation of GAAP to non-GAAP Financial Measures" contained in the press release.

Statistics (as a % of net sales, except for income tax rate)
 
 
 
 
 
 
 
 
 
 
 
GAAP Twelve Months Ended December 31,
 
Adjusted (1) Twelve Months Ended December 31,
 
 
 
2019
 
2018
 
2019
 
2018
Gross profit
 
68.7
%
 
66.4
%
 
69.6
%
 
68.1
%
SG&A
 
46.7
%
 
42.0
%
 
38.9
%
 
36.4
%
R&D
 
13.8
%
 
13.2
%
 
14.1
%
 
12.3
%
Operating (loss) income from continuing operations
 
(15.6
%)
 
(22.4
%)
 
16.6
%
 
19.5
%
Net (loss) income from continuing operations, net of tax
 
(14.3
%)
 
(16.1
%)
 
13.9
%
 
15.8
%
Income tax rate
 
16.2
%
 
28.1
%
 
11.2
%
 
15.6
%
 
 
 
 
 
 
 
 
 
 
(1)
Adjusted financial measures are non-GAAP measures and exclude specified items as described and reconciled in the "Reconciliation of GAAP to non-GAAP Financial Measures" contained in the press release.


14


RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - UNAUDITED
(U.S. dollars in millions, except per share amounts)
 
 
Specified Items
 
Three Months Ended
December 31, 2019
GAAP Financial Measures
Merger and Integration Expenses
(A)
Restructuring Expenses
(B)
Depreciation and Amortization Expenses
(C)
Impairments
(D)
Product Remediation Expenses
(E)
Acquisition Costs
(F)
Non-recurring Legal, Contingent Consideration and Other Reserves
(G)
Stock-based Compensation Costs
(H)
Certain Tax Adjustments
(I)
Certain Interest Adjustments
(J)
Adjusted Financial Measures
Cost of sales - exclusive of amortization

$78.3


$—


$—


($0.4
)

$—


$—


$—


$9.6


($0.3
)

$—


$—


$87.2

Product remediation
4.6

—

—

—

—

(4.6
)
—

—

—

—

—

—

Gross profit percent
71.2
 %
—
%
—
%
0.1
 %
—
 %
1.6
%
—
 %
(3.3
)%
0.1
 %
—
%
—
%
69.7
%
Selling, general and administrative
130.6

—

—

(0.1
)
—

—

(0.4
)
(15.5
)
(7.1
)
—

—

107.5

Selling, general and administrative as a percent of net sales
45.4
 %
—
%
—
%
—
 %
—
 %
—
%
(0.1
)%
(5.4
)%
(2.5
)%
—
%
—
%
37.4
%
Research and development
25.9

—

—

—

(2.7
)
—

3.3

12.2

(1.1
)
—

—

37.6

Research and development as a percent of net sales
9.0
 %
—
%
—
%
—
 %
(0.9
)%
—
%
1.2
 %
4.2
 %
(0.4
)%
—
%
—
%
13.1
%
Litigation provision, net
33.2

—

—

—

—

—

—

(33.2
)
—

—

—

—

Other operating expenses
158.9

(9.1
)
(7.7
)
(10.7
)
(131.4
)
—

—

—

—

—

—

—

Operating (loss) income from continuing operations
(144.0
)
9.1

7.7

11.2

134.1

4.6

(2.9
)
27.0

8.4

—

—

55.3

Operating margin percent
(50.1
)%
3.2
%
2.7
%
3.9
 %
46.6
 %
1.6
%
(1.0
)%
9.4
 %
2.9
 %
—
%
—
%
19.2
%
Income tax (benefit) expense
(6.7
)
0.3

1.1

1.1

11.3

1.0

(0.6
)
0.2

0.4

(5.6
)
0.3

2.7

Net (loss) income from continuing operations
(143.4
)
8.9

6.5

10.2

122.8

3.6

(2.3
)
26.8

8.1

5.6

2.1

48.8

Diluted EPS - Continuing Operations

($2.96
)

$0.18


$0.13


$0.21


$2.51


$0.07


($0.05
)

$0.55


$0.17


$0.11


$0.04


$1.00


GAAP results for the three months ended December 31, 2019 include:
(A)
Merger and integration expenses related to our legacy companies and recent acquisitions
(B)
Restructuring expenses related to organizational changes
(C)
Includes depreciation and amortization associated with purchase price accounting
(D)
Impairment of Transcatheter Mitral Valve Replacement goodwill, intangible assets and other long-lived assets
(E)
Costs related to the 3T Heater-Cooler remediation plan
(F)
Costs related to acquisitions
(G)
3T Heater-Cooler litigation provision, legal expenses primarily related to 3T Heater-Cooler defense, settlements and other matters, remeasurement of contingent consideration related to acquisitions and AR reserves
(H)
Non-cash expenses associated with stock-based compensation costs
(I)
Primarily relates to discrete tax items and the tax impact of intercompany transactions
(J)
Primarily relates to intellectual property migration, interest related to 3T Heater-Cooler litigation settlement and other non-recurring impacts to interest expense
*
Numbers may not add up precisely due to rounding.


15


RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - UNAUDITED
(U.S. dollars in millions, except per share amounts)
 
 
Specified Items
 
Three Months Ended
December 31, 2018
GAAP Financial Measures
Merger and Integration Expenses
(A)
Restructuring Expenses
(B)
Depreciation and Amortization Expenses
(C)
Product Remediation Expenses
(D)
Acquisition Costs
(E)
CRM Disposal Costs
(F)
Non-recurring Legal and Contingent Consideration
(G)
Stock-based Compensation Costs
(H)
Certain Tax Adjustments
(I)
Certain Interest Adjustments
(J)
Adjusted Financial Measures
Cost of sales - exclusive of amortization

$90.9


$—


$—


($0.8
)

$—


$0.2


$—


$2.2


($0.2
)

$—


$—


$92.2

Product remediation
2.0

—

—

—

(2.0
)
—

—

—

—

—

—

—

Gross profit percent
68.7
 %
—
%
—
%
0.3
 %
0.7
%
(0.1
)%
—
 %
(0.7
)%
0.1
 %
—
%
—
%
69.0
%
Selling, general and administrative
122.2

—

—

(0.3
)
—

(1.1
)
(0.6
)
(15.4
)
(4.3
)
—

—

100.6

Selling, general and administrative as a percent of net sales
41.2
 %
—
%
—
%
(0.1
)%
—
%
(0.4
)%
(0.2
)%
(5.2
)%
(1.5
)%
—
%
—
%
33.9
%
Research and development
37.6

—

—

(0.1
)
—

(0.2
)
(0.3
)
0.3

(1.0
)
—

—

36.4

Research and development as a percent of net sales
12.7
 %
—
%
—
%
—
 %
—
%
(0.1
)%
(0.1
)%
0.1
 %
(0.3
)%
—
%
—
%
12.2
%
Litigation provision net
294.0

—

—

—

—

—

—

(294.0
)
—

—

—

—

Other operating expenses
26.6

(4.4
)
(13.1
)
(9.1
)
—

—

—

—

—

—

—

—

Operating (loss) income from continuing operations
(276.5
)
4.4

13.1

10.3

2.0

1.2

0.9

306.9

5.5

—

—

67.8

Operating margin percent
(93.1
)%
1.5
%
4.4
%
3.5
 %
0.7
%
0.4
 %
0.3
 %
103.4
 %
1.9
 %
—
%
—
%
22.8
%
Income tax (benefit) expense
(69.8
)
0.8

3.5

4.0

0.5

0.3

0.3

74.5

1.6

(5.2
)
0.2

10.5

Net (loss) income from continuing operations
(209.5
)
3.6

9.7

6.2

1.5

0.9

0.6

232.5

3.9

5.2

0.6

55.2

Diluted EPS - Continuing Operations

($4.32
)

$0.07


$0.20


$0.13


$0.03


$0.02


$0.01


$4.70


$0.08


$0.10


$0.01


$1.12


GAAP results for the three months ended December 31, 2018 include:
(A)
Merger and integration expenses related to our legacy companies and recent acquisitions
(B)
Restructuring expenses related to organizational changes
(C)
Includes depreciation and amortization associated with purchase price accounting
(D)
Costs related to the 3T Heater-Cooler remediation plan
(E)
Costs related to acquisitions
(F)
Corporate costs incurred to divest of the CRM business not attributable to discontinued operations
(G)
3T Heater-Cooler litigation provision, legal expenses primarily related to 3T Heater-Cooler defense, settlements and other matters, remeasurement of contingent consideration related to acquisitions and AR reserves
(H)
Non-cash expenses associated with stock-based compensation costs
(I)
Primarily relates to discrete tax items and the tax impact of intercompany transactions
(J)
Primarily relates to intellectual property migration and other non-recurring impacts to interest expense
*
Numbers may not add up precisely due to rounding.


16


RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - UNAUDITED
(U.S. dollars in millions, except per share amounts)
 
 
Specified Items
 
Twelve Months Ended
December 31, 2019
GAAP Financial Measures
Merger and Integration Expenses
(A)
Restructuring Expenses
(B)
Depreciation and Amortization Expenses
(C)
Impairments
(D)
Product Remediation Expenses
(E)
Acquisition Costs
(F)
Non-recurring Legal, Contingent Consideration and Other Reserves
(G)
Stock-based Compensation Costs
(H)
Certain Tax Adjustments
(I)
Certain Interest Adjustments
(J)
Adjusted Financial Measures
Cost of sales - exclusive of amortization

$323.6


$—


$—


($2.4
)

$—


$—


$—


$10.0


($1.3
)

$—


$—


$329.9

Product remediation
15.8

—

—

—

—

(15.8
)
—

—

—

—

—

—

Gross profit percent
68.7
 %
—
%
—
%
0.2
 %
—
 %
1.5
%
—
 %
(0.9
)%
0.1
 %
—
%
—
%
69.6
%
Selling, general and administrative
506.5

—

—

(0.5
)
—

—

(1.1
)
(57.7
)
(25.6
)
—

—

421.6

Selling, general and administrative as a percent of net sales
46.7
 %
—
%
—
%
—
 %
—
 %
—
%
(0.1
)%
(5.3
)%
(2.4
)%
—
%
—
%
38.9
%
Research and development
149.9

—

—

(0.2
)
(3.6
)
—

1.9

10.6

(5.6
)
—

—

152.9

Research and development as a percent of net sales
13.8
 %
—
%
—
%
—
 %
(0.3
)%
—
%
0.2
 %
1.0
 %
(0.5
)%
—
%
—
%
14.1
%
Litigation provision, net
(0.6
)
—

—

—

—

—

—

0.6

—

—

—

—

Other operating expenses
257.8

(23.5
)
(12.3
)
(40.4
)
(181.7
)
—

—

—

—

—

—

—

Operating (loss) income from continuing operations
(168.9
)
23.5

12.3

43.5

185.3

15.8

(0.7
)
36.5

32.6

—

—

179.7

Operating margin percent
(15.6
)%
2.2
%
1.1
%
4.0
 %
17.1
 %
1.5
%
(0.1
)%
3.4
 %
3.0
 %
—
%
—
%
16.6
%
Income tax (benefit) expense
(30.2
)
3.5

2.3

9.3

23.7

4.6

(0.1
)
5.6

6.0

(6.8
)
1.1

19.0

Net (loss) income from continuing operations
(155.5
)
19.9

10.0

34.2

161.6

11.2

(0.6
)
30.9

26.6

6.8

5.3

150.4

Diluted EPS - Continuing Operations

($3.22
)

$0.41


$0.20


$0.70


$3.31


$0.23


($0.01
)

$0.63


$0.54


$0.14


$0.11


$3.08


GAAP results for the twelve months ended December 31, 2019 include:
(A)
Merger and integration expenses related to our legacy companies and recent acquisitions
(B)
Restructuring expenses related to organizational changes
(C)
Includes depreciation and amortization associated with purchase price accounting
(D)
Impairment of Transcatheter Mitral Valve Replacement goodwill, intangible assets and other long-lived assets and Obstructive Sleep Apnea intangible assets and other long-lived assets
(E)
Costs related to the 3T Heater-Cooler remediation plan
(F)
Costs related to acquisitions
(G)
3T Heater-Cooler litigation provision, 3T insurance recovery, legal expenses primarily related to 3T Heater-Cooler defense, settlements and other matters, remeasurement of contingent consideration related to acquisitions and AR reserves
(H)
Non-cash expenses associated with stock-based compensation costs
(I)
Primarily relates to discrete tax items and the tax impact of intercompany transactions
(J)
Primarily relates to intellectual property migration, interest related to 3T Heater-Cooler litigation settlement and other non-recurring impacts to interest expense
*
Numbers may not add up precisely due to rounding.


17


RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - UNAUDITED
(U.S. dollars in millions, except per share amounts)
 
 
Specified Items
 
Twelve Months Ended
December 31, 2018
GAAP Financial Measures
Merger and Integration Expenses
(A)
Restructuring Expenses
(B)
Depreciation and Amortization Expenses
(C)
Product Remediation Expenses
(D)
Acquisition Costs
(E)
CRM Disposal Costs
(F)
Non-recurring Legal and Contingent Consideration
(G)
Stock-based Compensation Costs
(H)
Certain Tax Adjustments
(I)
Certain Interest Adjustments
(J)
Adjusted Financial Measures
Cost of sales - exclusive of amortization

$361.8


$—


$—


($11.6
)

$—


$—


$—


$3.5


($1.1
)

$—


$—


$352.6

Product remediation
10.7

—

—

—

(10.7
)
—

—

—

—

—

—

—

Gross profit percent
66.4
 %
—
%
—
%
1.0
 %
1.0
%
—
 %
—
 %
(0.3
)%
0.1
 %
—
%
—
%
68.1
%
Selling, general and administrative
465.0

—

—

(0.9
)
—

(5.5
)
(3.8
)
(32.9
)
(19.4
)
—

—

402.5

Selling, general and administrative as a percent of net sales
42.0
 %
—
%
—
%
(0.1
)%
—
%
(0.5
)%
(0.3
)%
(3.0
)%
(1.8
)%
—
%
—
%
36.4
%
Research and development
146.0

—

—

(0.3
)
—

(5.4
)
(0.3
)
0.2

(4.5
)
—

—

135.7

Research and development as a percent of net sales
13.2
 %
—
%
—
%
—
 %
—
%
(0.5
)%
—
 %
—
 %
(0.4
)%
—
%
—
%
12.3
%
Litigation provision, net
294.0

—

—

—

—

—

—

(294.0
)
—

—

—

—

Other operating expenses
77.5

(24.4
)
(15.9
)
(37.2
)
—

—

—

—

—

—

—

—

Operating (loss) income from continuing operations
(248.1
)
24.4

15.9

49.9

10.7

10.9

4.2

323.3

25.0

—

—

216.2

Operating margin percent
(22.4
)%
2.2
%
1.4
%
4.5
 %
1.0
%
1.0
 %
0.4
 %
29.2
 %
2.3
 %
—
%
—
%
19.5
%
Gain on acquisition
11.5

—

—

—

—

(11.5
)
—

—

—

—

—

—

Income tax (benefit) expense
(69.6
)
5.1

4.0

12.3

2.5

2.5

1.4

78.2

6.3

(11.0
)
0.8

32.5

Net (loss) income from continuing operations
(178.5
)
19.3

11.9

37.6

8.2

(3.1
)
2.8

245.0

18.6

11.0

2.4

175.3

Diluted EPS - Continuing Operations

($3.68
)

$0.39


$0.24


$0.76


$0.17


($0.06
)

$0.06


$4.96


$0.38


$0.22


$0.05


$3.55


GAAP results for the twelve months ended December 31, 2018 include:
(A)
Merger and integration expenses related to our legacy companies and recent acquisitions
(B)
Restructuring expenses related to organizational changes
(C)
Includes depreciation and amortization associated with purchase price accounting
(D)
Costs related to the 3T Heater-Cooler remediation plan
(E)
Costs related to acquisitions
(F)
Corporate costs incurred to divest of the CRM business not attributable to discontinued operations
(G)
3T Heater-Cooler litigation provision, legal expenses primarily related to 3T Heater-Cooler defense, settlements and other matters, remeasurement of contingent consideration related to acquisitions and AR reserves
(H)
Non-cash expenses associated with stock-based compensation costs
(I)
Primarily relates to discrete tax items and the tax impact of intercompany transactions
(J)
Primarily relates to intellectual property migration and other non-recurring impacts to interest expense
*
Numbers may not add up precisely due to rounding.


18


LIVANOVA PLC AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS - UNAUDITED
(U.S. dollars in millions)
 
 
 
 
 
 
 
December 31, 2019
 
December 31, 2018
 
ASSETS
 
 
 
Current Assets:
 
 
 
 
Cash and cash equivalents

$61.1

 

$47.2

 
Accounts receivable, net
257.8

 
256.1

 
Inventories, net
164.2

 
153.5

 
Prepaid and refundable taxes
37.8

 
46.9

 
Prepaid expenses and other current assets
28.6

 
29.6

Total Current Assets
549.4

 
533.3

 
Property, plant and equipment, net
181.4

 
191.4

 
Goodwill
915.8

 
956.8

 
Intangible assets, net
607.5

 
770.4

 
Operating lease assets
54.4

 
—

 
Investments
27.3

 
24.8

 
Deferred tax assets
68.7

 
68.1

 
Other assets
7.4

 
4.8

Total Assets

$2,411.8

 

$2,549.7

 
 
 
 
 
 
LIABILITIES AND STOCKHOLDERS' EQUITY
 
 
 
Current Liabilities:
 
 
 
 
Current debt obligations

$77.4

 

$28.8

 
Accounts payable
85.9

 
76.7

 
Accrued liabilities and other
120.1

 
124.3

 
Current litigation provision liability
146.0

 
161.9

 
Taxes payable
12.7

 
22.5

 
Accrued employee compensation and related benefits
70.4

 
82.6

Total Current Liabilities
512.6

 
496.7

 
Long-term debt obligations
260.3

 
139.5

 
Contingent consideration
114.4

 
161.4

 
Litigation provision liability
24.4

 
132.2

 
Deferred tax liabilities
32.2

 
68.2

 
Long-term operating lease liabilities
46.0

 
—

 
Long-term employee compensation and related benefits
22.8

 
25.3

 
Other long-term liabilities
15.4

 
22.6

Total Liabilities
1,028.1

 
1,046.0

Total Stockholders’ Equity
1,383.7

 
1,503.7

Total Liabilities and Stockholders’ Equity

$2,411.8

 

$2,549.7

 
 
 
 
 
*
Numbers may not add up precisely due to rounding.
 
 
 



19


LIVANOVA PLC AND SUBSIDIARIES
 
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - UNAUDITED (U.S. dollars in millions)
 
 
 
Twelve Months Ended December 31,
Operating Activities:
2019
 
2018
Net loss

($155.2
)
 

($189.4
)
Non-cash items included in net loss:
 
 
 
Impairment of intangible assets
139.3

 
—

Impairment of goodwill
42.4

 
—

Amortization
40.4

 
37.2

Stock-based compensation
32.6

 
26.9

Depreciation
30.3

 
32.7

Remeasurement of contingent consideration to fair value
(29.4
)
 
(4.3
)
Deferred tax benefit
(26.3
)
 
(95.1
)
Amortization of operating lease assets
12.3

 
—

Impairment of property, plant and equipment
3.2

 
0.6

Amortization of income taxes payable on inter-company transfers of property
2.6

 
13.4

Losses from equity method investments
—

 
1.9

Gain on acquisitions
—

 
(11.5
)
Other
5.4

 
2.8

Changes in operating assets and liabilities:
 
 
 
Accounts receivable, net
(5.3
)
 
21.2

Inventories, net
(10.6
)
 
(10.6
)
Other current and non-current assets
(2.1
)
 
(13.0
)
Accounts payable and accrued current and non-current liabilities
(31.8
)
 
4.5

Taxes payable
(8.4
)
 
2.7

Litigation provision liability, net
(123.7
)
 
294.1

Restructuring reserve
(6.7
)
 
6.5

Net cash (used in) provided by operating activities
(91.1
)
 
120.5

Investing Activities:
 
 
 
Purchases of property, plant and equipment
(24.7
)
 
(37.2
)
Acquisitions, net of cash acquired
(10.8
)
 
(279.7
)
Purchases of intangible assets
(3.3
)
 
(0.8
)
Purchases of investments
(2.5
)
 
(3.8
)
Proceeds from asset sales
1.3

 
14.2

Proceeds from the sale of CRM business franchise, net of cash disposed
—

 
186.7

Other
(1.3
)
 
—

Net cash used in investing activities
(41.3
)
 
(120.6
)
Financing Activities:
 
 
 
Proceeds from long-term debt obligations
197.2

 
103.6

Repayment of long-term debt obligations
(24.2
)
 
(23.8
)
Payment of contingent consideration
(19.0
)
 
(0.7
)
Shares repurchased from employees for minimum tax withholding
(7.1
)
 
(11.6
)
Proceeds from share issuances under ESPP
4.5

 
—

Debt issuance costs
(3.8
)
 
—

Change in short-term borrowing, net
(1.2
)
 
(30.7
)
Proceeds from exercise of stock options
0.4

 
4.2

Proceeds from short-term borrowing (maturities greater than 90 days)
—

 
240.0

Repayment of short-term borrowing (maturities greater than 90 days)
—

 
(260.0
)
Share repurchases under share repurchase program
—

 
(50.0
)
Payment of deferred consideration - acquisition of Caisson Interventional, LLC
—

 
(13.0
)
Other
(0.2
)
 
(0.3
)
Net cash provided by (used in) financing activities
146.6

 
(42.3
)
Effect of exchange rate changes on cash and cash equivalents
(0.2
)
 
(4.0
)
Net increase (decrease) in cash and cash equivalents
13.9

 
(46.4
)
Cash and cash equivalents at beginning of period
47.2

 
93.6

Cash and cash equivalents at end of period

$61.1

 

$47.2

 
 
 
 
 
*
Numbers may not add up precisely due to rounding.
 
 
 

20


The following table presents the reconciliation of GAAP diluted weighted average shares outstanding, used in the computation of GAAP diluted net loss per share from continuing operations, to Adjusted diluted weighted average shares outstanding, used in the computation of Adjusted diluted earnings per share from continuing operations (in millions of shares):
 
 
 
Three Months Ended
December 31,
 
Twelve Months Ended
December 31,
 
 
 
2019
 
2018
 
2019
 
2018
GAAP diluted weighted average shares outstanding
 
48.4

 
48.5

 
48.3

 
48.5

Add effects of stock-based compensation instruments
 
0.4

 
0.9

 
0.5

 
0.9

Adjusted diluted weighted average shares outstanding (1)
 
48.8

 
49.5

 
48.8

 
49.4

 
 
 
 
 
 
 
 
 
 
(1)
Adjusted diluted weighted average shares outstanding is a non-GAAP measure and includes the effects of stock-based compensation instruments, as reconciled in the above table.
*
Numbers may not add up precisely due to rounding.


21
 EX-101.SCH 3 livn-20200226.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001000 - Document - Document and Entity Information Document link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 livn-20200226_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 livn-20200226_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 livn-20200226_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover page. Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Address, Country Entity Address, Country Country Region Country Region City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag EX-101.PRE 7 livn-20200226_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 8 download.jpg begin 644 download.jpg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end GRAPHIC 9 livanova8ktemplat_imagea02.jpg begin 644 livanova8ktemplat_imagea02.jpg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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Document and Entity Information Document
Feb. 26, 2020
Cover page.  
Document Type 8-K
Document Period End Date Feb. 26, 2020
Entity Incorporation, State or Country Code X0
Entity File Number 001-37599
Entity Tax Identification Number 98-1268150
Entity Address, Address Line One 20 Eastbourne Terrace
Entity Address, City or Town London
Entity Address, Postal Zip Code W2 6LG
Entity Address, Country GB
Country Region 44
City Area Code 20
Local Phone Number 33250660
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Ordinary Shares - £1.00 par value per share
Trading Symbol LIVN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Registrant Name LIVANOVA PLC
Entity Central Index Key 0001639691
Amendment Flag false
XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } EXCEL 15 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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etaLinks.json IDEA: XBRL DOCUMENT { "instance": { "livanovaform8-k4q19ear.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "livn-20200226_cal.xml" ] }, "definitionLink": { "local": [ "livn-20200226_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "livanovaform8-k4q19ear.htm" ] }, "labelLink": { "local": [ "livn-20200226_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "livn-20200226_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "livn-20200226.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "livn", "nsuri": "http://www.livanova.cyberonics.com/20200226", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "livanovaform8-k4q19ear.htm", "contextRef": "D2019Q4", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Document and Entity Information Document", "role": "http://www.livanova.cyberonics.com/role/DocumentAndEntityInformationDocument", "shortName": "Document and Entity Information Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "livanovaform8-k4q19ear.htm", "contextRef": "D2019Q4", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region", "terseLabel": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 17 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 1 96 1 false 0 0 false 0 false false R1.htm 0001000 - Document - Document and Entity Information Document Sheet http://www.livanova.cyberonics.com/role/DocumentAndEntityInformationDocument Document and Entity Information Document Cover 1 false false All Reports Book All Reports livanovaform8-k4q19ear.htm ex9914q19earningspress.htm livn-20200226.xsd livn-20200226_cal.xml livn-20200226_def.xml livn-20200226_lab.xml livn-20200226_pre.xml livanova8ktemplat_imagea02.jpg http://xbrl.sec.gov/dei/2019-01-31 true true XML 18 livanovaform8-k4q19ear_htm.xml IDEA: XBRL DOCUMENT 0001639691 2020-02-26 2020-02-26 false 0001639691 LIVANOVA PLC 8-K 2020-02-26 X0 001-37599 98-1268150 20 Eastbourne Terrace London W2 6LG GB 44 20 33250660 false false false false Ordinary Shares - £1.00 par value per share LIVN NASDAQ false ZIP 19 0001639691-20-000014-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001639691-20-000014-xbrl.zip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

^8.SB8PIO&0:A9RFJ4-- MQO\0 GT$GPIHH/<.(V"W@1QJPL?!Y0("M@MB!#R)%\Z4&WZ//.H$\5,,K2X^ M57]ENF4%ZCGHTT.A-SU?4((M$XX[Z^5N^<[=ISL6\HRY#.%6+\SM*K9Z2S:M M=UP3?2?2$8[C/0H=%NB?6;1@.:@M408C=LVNL+JI:3Q_/:PSS].V3MMKZ_5H M86YQAUQXOG3KPK1@_._83Y\P!5=W=@]A]8\S.H07GE/GD3X%)]+.T2Y+)7-U M:DKY]\YMJ>UR/R%^9Q_G>OX$.)HUOR((@4?&BF$RQTG._O-$.Q&_@RDUT]_; M3ZO',Z>];KV;_:_W]OV]YX.Y.#-!->DT8.?I'ZNFK4+@4\C]//\8]Y\GNL[G MWD.+_^//3B.ZE4XU\MQ7_Q)RW-5]UVPJV05@8\D1]PGK MQOMGV#(6_';V=^+:LX=$-8$XD@A:/$2?_B2!YT"<](LF_DO/"B@NG7P.]?7: MV=G.CG12;R:N/;=#>*C)AR(\R$DRO M>*V7H#(+MDS6,F]B6Y;!YS]73ACUX+R M2-SJ!\D\,[")O(4A A]"E)5',L)QD":RR"#-9*V-F_;P^A=$6A[+^UKCFHL' M2X.%DP\?DPB6O"/??,^*S! &P"X[WX#[Q@:L)T2F.94E,LOKQ(I"6W:$(3\3 MRVE0@,?=8K19+Q4&"]/UA5!J0'W+]J:1 R$!]9]6PW,UQV(>[ 62)>#@%D/M ME]FTI>9NYLJ6=,?EPGN SAN]8=3;>T#,7@S,L<2/6E)U+6FVZQW4DD+%?VPM MV1M:3GO;6=0M^3:/45[/N*,"[-6,>_L;PBT'W+KU)L*M*+CA(&,-M_YDU _) M7]1Y8)O2M6LS9I+%47M3V8:QN-RNRM$$XN:UN#&Z.%93;*RV-ZSHQG9AP99\ M4S@L0+3E0%NSKB':"D(;QJ!KF/52]2O&%KOQMEM?->=2T= "8?-:V'3V$F5( M"AM,5+T8(_2VRZ%CHBI/1(IHFZ%M*X>&:"LV(E4N($WK+!YHP&-/'R.';7BG M=QKU%D8*"),-,.EB.0HFG59"X[2%*:97L&F[2?2*0JFQEV1'):"$H2"__II% MOC?Q+)Z$S&R=@D[^54Y>;^#\-\+D-3#!6! =^"H'KN'D-L:"A4!)VXLK4@Y) M,D2"963);3C-M)3#M@ FL7:!D()1VFLQ\)[;CG!VWMMBX='GCW-YV M']=;,[(K;(=0LLRX53MXZMVIV)DT@>L(&S2)\?Y!KN>>B5X0$Q;ZMEG?!/-C0WO= M^_>U)W7?<9+MID>^]QB.B4]#^''/'.^1^&SH,#-,&FYP!M56-.:(;UPEF^21 M-.Y>--_1VH;'P6-%&X>A$YEAE'1O2#:_?Z"^Z.>1/,B.M\5_'-OF6)P?Q&W: MDJWAX>Q"4Y!9AY/DTV3JS'" GGPO[9;^4A7OH1GW_%MBF-82&-BNZ406.('G MN[N![1#[.?)>$6)+A@>Q)8-H)- ?W-9V; ?$RW1W;KP&Z/19P.)V7C1_Y[6\ MK4J>-=N9]28"KQ#P5@P%;SA?D7XJ^_B"V[2MR3J,[PAFOK==P6!V\WY-9I<> M-=%\-X;().V<(-H[N6Q$>1L6"'-B?QCWM&$_[<0P#*A++1MX^JS5"QWYC(D6 M]B]TBDFM) .JP]@GONG6.ZFTTUNGX&;]N-L3<-#V+&$G^9FU?6Q$"YIYZZTK M-YC:/LO)EM_AX2]$I2]$RYUIR$6O=YKO09SPF \Y/V'>DZ=>>8/SY]QCILXV M=K,/!MFBEFW6R.SI7ONW/[DU-"VEDE]VO8;=0:Z$C]);?,1O; M+#2\*X=)J[JZ0#Q91#??;KV[(^P%Q!*3GF"B,$WH%1-FEA'!->[_)C#4=)ZR M;BT9M (_O_E>R'Y<1-ZF%ZPH2BC0P>WDWV:-F^[@'S81)EYVO"A%G-@0"D2WZ['2VNSGVYYT;W#SBQ[9(>SG&T)C6A9 MM?W3K"OI-^8/>?LZUV3'Y=]RI^M2-+9/.K:"4HN&UWMJT>G.6,DGG+EP6IO,7W<7RV#F8)_9&/IT(-<\]C&[4C2)L-J?7L4-[%'^\[3YX MSH-(!,PG8/ZO@#3N",240,G9P/,<(,AB#[;)ZJ2?]O&>HP&X[$U>[-Y=NI:G MNP"TU:HW=D]HS'.:.XSB"DJO+DRS<4GE?&PLX%V^Z>A.V8[-UWP,:?G@?%V> MPYW.'00?1RZ$9C4R:Q<.6@7>G&=S7V[\#OT[WF..ZT@S5R]5- IM-4&I7?C MW]G'N3QD=)X5$NM)$6AA!:\+7YN4MVI 1U)];(+@Z#1@Y^D?2ZG?>8WL;%V( MKJ?%L2MJ8N-W-+5]-I$_P!,;^[RM=)L%[%:$WMG.ZW123RFNS306Y&.09 "] M:?U7>P]]R/?!J<*ZW#\RGC&2KLU]*9G9#V#8G90,$_)"RW0)6%C.IM6SVG R M2,.6M2YV#Z]_0:3E,;U[7>*S-!(Y^? QK49\QRL=>$4I^0P'SC?@?E,#=_7- M10%=[BO!)&Q3_Y(R+@0[V*9^#0>Q ?AU:3ENX458NQF&;^EQPVW+/;X3;2W##0<8:;F&;^@);J!D:;L6*P,D#G#8" M1['1VOX"@_V,["L:&"#<-L%-0[AA'(JMZB56X8:^7>9"[>@"AD]^&>4VCB5DCA,EFF#1P MRAL=^"IH8*_Z5_EO!-(F%NG8Z"LGD# .Y-=C+_JM689.'4&R$23&7B9O) 7) M:IJKN H"K$=WN]1-)=<\8"_ZUPPOMRRH1B1A+_KM=MO!7O0'5.DWK-M<- MYY#-Q;%9U[ ?_6LFF?83PRKG7W"^\A7I3D32#I$*=J/';O1[Z$:O4!_Z I,6 MZ[X!>]$7V8O^V$WC&@M0M+!IG-H[Y[]4^WQHQCW_EB*:UHGJY(+;FN??][V0 M;A6+7R UBMOM(-$*C(Y^)#DDO-6Q*^\JQ?T=I M1SC>W[PWZR:7W#N%V,*/.0&\LCU+M''B9W@(X;G\-;SQDV,SG\0-V!>:S%VY MP=3V64YF[-C0E^S4R]?[^31B+E_[7?4^E.G&3 ^B"Z!P@K6D)R&'8AA+GD-C MPOCX@HN)C.>WP-6[=4?A6QF5HU5=7I>Y% $E)BCG9ZSJ6WYD/;HL( M#_GN"+LCW9VW"\X/]>RRUEV\:Q:CAT=F+=,!,>.;DN$V^+EOOA>R'Q>1)PP8 M^#2>7K&Y+P4CEFFW%J1A%=]>/8T4^(>1P.:-%.,&]I_M(1/.FYK_CFQ?]% D M??@$AS^#7U[Y"'7)%%:YA[E8H%!4/]QCMJDJ*J3/E,GN8G1F]J\\'O)VCI9Y M*U9J>=-L]^5;YM[9#_0X\?*OO^B=YON=@F8AA+^N;WF7-9].G^0FY/8I"%G< M[QJ^X@EN]ST ]]QY<)%=@E&8QN'OJK%64/78:"M[+T47^V-W SQ0 _MV=^=8 M=-<^Z\?F]$[\Z_0*2)05TY>X7=^)#6OZ$A_3GV;C^C@[QJS7]#9?:&F>MB3/ M=##?V)D\T^)\X6E\$)AFR%;GW59T-1_2!T],&*8)6L#,3_&8N+\Y$#F"9V>; MGV,CYFV:(QL:^2.RK>-[DL\0V5U[#Y2PGU-F/NLUZW)0Q/UF7S:+TP@!<:#7!L:>Z%U>:5FBJ>_&K\BG8E2OP6'M6^0!V&!P%+WT(N<6E M*>9-&HS)D-=N"(C/<5T#+*>Y;0?L_B@>[4_IDS"^-?((/GTEQH$J 7%#FZ6K MZV1 IWS',Z$@KF6'D<^K,'QA[O\U4YGX(:D:OS%:L:[,<@,5-_DG'T[^9K&= MX;K&12,LSZ/-BV;XP(S[;'"FGAD%/-IT(6YRP%^+2WE[;^8_*][A0@9X""%G M_6P@#&CL;/DY@9(1GF5;Y(MYP=.$5IV(P]K[Y!OCL"".=0E/ MBE#?'(L'6^R!.=Y43-"!@&F\T3#Q(I],[2GCG!37\3J@R=2QX>4!W.+S6&/" MPQ,PXQP2\'C/3;J33^'+1 0BF'%A#X>V&3GA6>B=W8&U",F%R,P$(@")9W(^ M43#X?ORJK_? /0@[@%GDUF%L2OI3E]%Z0FFU<;=5J/$WNP>XA(*K \\=,NYL MP1!1,!=7;L+EI5[1AV;I7<8V"DLV]O@W$ZXMA(+9\\AC0@A'E\WUC0F+"8%_ MR O,1 #LFB+/%Q*=3.N3.OGLN19H'=A:1DZ[A/)CE_ 0YKN$5Y+^QG7R;V8! M:BWZ5".?V+T?\;($HQT;YM2J O0Y6'E '(Y]+QJ-DYEDKE/P03?,2>*/@)G9 MW-DLO(+/#^R0\8_+-;HP/G_&]!UV9,?GU MG[6PU$%O+RR'X.7S>QU]?OL\^/47O:V]!RVF9.1X]V!')LP291LA,\=$1NR+#0,;RW,H.;V"0=#3;_PI\9O_]"(> MQ,8_3H6OX9.( 4\C@ "=IZ.ZEJ7 [^3#)Q"($);MBA1CS("I$Y<.VF!B90DW M7F^L]F.RCYUH6=P24.5$RP$\X?=X*4 MT(88Q%I^*WS1?1.;PV@,NX!EXTC%?J ?<XAY&,/:887'L/\6$^\5SV+#V>Y5"8\$0*P&$8. M 8//;V)A7U01P(VYX_.S";LQ$) M@3"=K%FW9K"67;ZY!-;:'+4BK9 L_TR+U]*$<_I1G(BEJG^N*T+G>2)RQ*=Z MDL?,Q,A /4%P5C0S3Y2O"C"3:)\S;2]H/ M\H@SS"(UQLM$N0WBH_T$@!Z,<8C)_)!R^S^)%W3&.:[4;L35\W%YZ)KWU D/ M.-E/"N,'$./2%\YF#!,0)],)(A,@$N7)O(?UXB2@D'@\W\$6EIIPJH#Q9'9# M=OVI^+K5+)O-L(3TIX!(/ Y\Q5SC*)FFG7U0;)MM,80)(IY##^;&U0'3'L^> MU!)<"RP.*0P;N=K&VN:)@L2X$#FVU;&KIKZ8IS;%LP _W;8MWI1Z!N]]E =FS^6QBW)W&+Q?@T6S+W/>'AQ!#P[/G/EJRL@M"< MX)7@GQF]K!;4$G5)INVG'C?8@D9>_AW8L3:"\"Q;S B)R;\:$;$3/\SKMYC@ M@EAN-;N=RX!_Q7PTSJ^.M4% -1 ,%S,*L.3&'E#K)ZF;D(U2L'/!V*'( MC^RJ*FNU8;T6S<(U@:.YA1'V1B@WO?<>V+JKX)=#'V)\P8H, $<268T2:JO5;9%!*XS_4)'>%PWR^'R>(_G 2.7%VEYKC@( M,/+\\,AN+G>R="\S3=0)O'F<-K-'JX+KV,[/KXFG9WF:"X;'\\,!<_BT12V9 MG7420S>Q75M,!W.S)>;< Y:Y:^UL[/*E,TH>#F0R#CY[L-EC:HAG7[*0.DA.)^G_FBB59/Z#&*;2Q%?S^"28 MU4U.'>JZ0C63,1'X!=#)M%[&8@'WK,+C3#C^8Q_"5U&Y0FOY_3S C'RN@3SE M6GO18@"IWF-2= &.?FG M/QF13;5H>\JT#)+199!^WSR;LI#E3$(E/K\T!6T!HP 7\3RB^3QW&5N5I(YI M,1Z:OR:M?\I4%H >N@*.,0:_^6"'0KZ4"0 8J\'G>17=#4_832!:$Z&=WNNU M:OQ*<<[H].?KH&8WSRYMQ,6MLZOURQ577Z9A^ORV9DV8J@D?%EB;IDQ6N)*% M29,M)24*Z..4XC-AB:%B/)A-U3P[&IG/TB5&2QA%$*<8$,6%Z*G%Y7^O3ON* M):U1R,4(AANLFY6,[.*L1&R?X:VQ](81'Y_$)6_9327BH#^(:Y9%#;*XCCW, MYFK!]GI\;X ?KO?HBB.1&__MV\&/C#6STNJT..W%[6((L7L@DLX!'*^)6CC* M1UA.AJCX)/^0.74@5G/,X\ED*.EGOI(GA&.+SD<(C(LF21W#MWB!B RYGO 8 MS>=C#0A,TSQTL#P>F$NN3JY<4;[/V<09_^1%\">X+S[F!-U^X=XTSQW%YO<1 M3/(\W$TT#SY\5F.8'#)Y?F'Q8,#8C\5C:?ID\7C"YZ7#Z7!S\81C_P [L7@T M"=X7#_-2DJ6/&Z_ZY+A"?/$HA4\P[2G/+2Q>GR2PEKX;-&'Q&!_LNDMO3/-R MJXX# V>'/3].)V1]*<@(<#.)\9W,(J2HB74BF9]WV2@>;"S.K)RECY-'9(U#\.9FI)]>LXG:N9)6W2695%.L'J MC2((K4!\JSF70.B9/\:>PS\EG7_A=P,83%%)%>\]8\;H:3Y &'+$\>:>1)/2S 1 MT"?&*UXL'2\L9:EIK8D5PN*S@:_P%B'#=(M D?QRXLV!N+$4@X*$-;5,57DF MF?>J4<4+!?'FBAKV6C*$%MM0)HDBCLL)KT+[3WP@7B&B]VI)I;, $'QR.G.1 MDIGFE!P*C!TG"!]&">+@!O;OB"?Z,NNM> $WN'T1-O.:MXCG@_P12SR2SSC? MTMM%63C< >.BI+")S_;:T[C>.A#I\61X,[2=]*Y//%+1M;/_-QX*\-)6YRD- M^6?I+RY "+EC=Y'_&&A'CIW2BQ&7,$LCG;S1Y2Y(3(Y M)Z?V;W'BSDW3K]E9,'C0A+$P60Z46%0?3*1OI13' 8=81S=UV!PX\=:7J8VA M/WG 0F-AOX>WVKQZ=02AYG_24:I8(^<]\#D8KO5I.I2)J^%RL(%)Q;7(R">\ M)8' L!B>D@#@;G'!92](5WK$@[UYNG1V@<4FZ:3X;%,U8:2X7$TF/O?A-S 2 M<^>,RVG5%KSH(99&*@MXZ-A.*OMC M'2 _F%@6":[ 90Z_PWY^2^E23(MM5U1.,1UJP,BS,"&,%TQ>H/*X8&@2H+"? M=IR&F)]-AW@4L,.G%69P%C@"(&74PX&A2)!LC0*:$6LF5R1A9T916J9,XUDE M>$^*Y_AA\+1D1C76[QI)_XJG2OB E>?UO8EM@E/UQ," JZ#'5VGQLW#2LN=:_/.W[$,3;I@\GN;&U/_! MA&V"JY[%0_&8.S-Z$7%#&A?--O5[I8;_Y*8LCCP"036W)B+;%+ P=.((#DQF M9JW:8H XH1:+9R5!CO'P63S ]!/.98SO\S 3A,K'E+YG@I_B$8/X(/BBI0'J M,]D]BQYBTA;F\\3*.4'5K"9B88HY+3P2\W"SZ3>>._4])_D.^[?9I-%\]FRV M;&7V-7QVAA?CI_ AW.:#JQ! C2?]LM\AO#3W0'Q"*PB2>$,,A,FMS8MZ?:Y\=ESK)<;XZ5S:;)8K41W/CV>LDA!7 M7!5/(7,6Q0E!OH1$!-&I*PF$]V8_QY3;D0=6)_\#P]4D?.8%PGPY\=-LS!!O MNC![7/J8E,/)]ZP.@I/H.=:P55G75$.>;1THQN+6K-8I4;!DF'8#;R*?XH^8 MK;N;KX+HNRX/86[$#M8B73L+V&KDO^,"-R!NQ?G_SFBI!:%A4A)N\_JP.$? M5S%QD/+_%YHBUL.X(@@2.<$@FW3B3YLEG@:\QET,]K*CKBV*F1=[(;0.5;[U M]VPP)+(:'#H\2[-FA"6FUM>.LK):+ZR/YSIBHCX9/UH\12C^7DQ9QJ!.,]F6 MQV(0BU%H2'\PH4S1G#4Y"]TG](WOC#D7IDZC7=' MCRO2GD?+->%"LW6?BTFQ9[/L64/,ZSCF9Q(_D:K9S"^^Q%8PA&PZLZ" @G@F M)]EMCL\FS"NO'/H(0X$A#$92QO#][=(R]I?>XGJ M133A(LELF1>_*%F,FA2%Q%_+57UFU5X8GZ>:DM&1I5X/ OZVJ/,0O[-*Y'*Q M.,]5)ND/45@OC(SN\ T%DLX7&FAOTI?$]!R'3@-VGOZQ%'O.VV?,6D;I:=N, M%=TR,J]XX:I-C7$72T%?U4>J'3-OA3SX(_C9XA=;? %+$P04S#^,>'/OAP;Q M]U\P(!-+Z42"MK9JW1R_[!M?4WE._F^=G!I=_3=B&%W2,=J&.,G.)N"\SV=3 MC'YZZ_\S,^^9U1BO; IS[%%6=Z=1%H7@? *7!8-/_7ZO.VCH[=;'5J_9[75[ MK8_-KJYKG_1.0_O(P4KST%F2 =I&[N?=@D1,#*W]1T(C&&^@$'\>A!%>>B V M(N)(47:RO=%0-N9FV7G5;5G99T:[Q94FO ML6+:(KZV05B.?DTKG-GGJ[_ZUU__ZO.EM^N\1"48<7UY1V[[GR]O*\T%L=@5 M1C9@\.(46[+'3["J0>'F(&^/G. I/#XC=#ZV+7 SQ;@]OMXW1Y-!I*_T],W5 M]AC-;]\)0VHJ($J,C7 M]OL D)DMSW\.FJVW!%KSJOP=,=J\(\:I_MOS=AB;!MZ;I"WCN'OPO"%FQ?5Y MDWM7@%;5Z4-9JD/?42TORA)EF8=6-4.'DP_?5TU05 "XA=/W6BD5V,AC*UKR M?+J0U:X(>]/4ZWD23&5G*((?P?\*\&OS-I\(_FJ!OQ $->N-'>B8\[Q +%,UU'S6ZKN:>B9QD-!JU34,$A!,A8"IW:OG MJ1Y$,&$$D$:>=%U*GF@IVU(KD?/7'A6BJWC#J MB]T77B/R36S(1Q)&)HCCG#ANYDO+(H[+B6.I A[Q:V$Y?B^762U; +2",@S! M)45DM]ZL$"+5C-%74/\GHWY(_J+.0^57$^**%>GI0UFJ0U]E5JR@+-6A5]VOA>@;$4F%8PH5AI<*29/@YU36L6D3 (>!P"AE7R*@7'F"%&6*I ML*G8?(8;P82N/W']^:R1))X?\58ZO'64F!FM6*2)"V2D#A(ZN0J$,4A ,*T MDX[#EW*!23( -9NJ1 (-QG@ULZU.E0.N*D:;^+BF,HM*F@8N8)47%. ,"X3 MC(TN+O%2",92!3OBU_."==U0(MA>01E&WW("LJE$./Y*0*H9GZ\@OF\]4-=D M%AG8OADY-/3\)W(;3:>>'U9347%QA3KTH2S5H:\RBRM0ENK0JF8<@0ME))S_ MZ]9;./V'6"H$2QU<=%4N+$F&'UV-;38PF85P.SK<5 TQ<9&,E*$!]I=#+"&6 M%,629/BY?M='_"!^*H(?50-!7,,BMP_')2R(I6*P].LO74,W\O@6Q!/Z=!E] M.N('\8,Q(:XSP0+]#]UQ/A]17"84Y]M% U%<3A1+%;N(7PM%_;U<_8#* M-C&Z@C*:,"7F/C55$UBK MS%H$E*4ZM*H9.>"Z$@DGY5JM7!MG8%8"P;0"3 TL^2L7F"0#4#/7*K>RY0\P M?X5H.S;:5 TQ<5V)E)%!LY5KJ@(C P33"C!U<"_LQ-08)"*85U:LZ9LG+!2;) '2JYT.0)"$ JY\ M@--4V36G2C$GKHRIW)H"O=/(-0^!JPH0QZ7"<=? 'BP*X5BJ@$?\>EZU?MI2 MMN4%AN!R(K*A[/*8ZL3H*ZB_9I'O33R+-V"Q/;>:RHF+*M2A#V6I#GV5652! MLE2'5C5#!UP@(^/47P\[KR"8"@)3KYEK4@;!)$_(L.=IO5:N%59E2R%@#@OQ M5@*\J1IFXB(9*:,#W<#ELPBFHL"DX8JK$6^G@UE-E M>4V%PE5<75.]50EZ(] 5E6)D@ M)R+SM2J6 9"5B=!7$/\U!"A74R%Q%88Z]*$LU:&O,JLP4);JT*IFP( K:B2< MZ?OUEZZA&WD,#N8C$$^()RGP)!F&KM_U$3^(GXK@1]5@$->]H -' XQX0CR5 M#T^284@NAX[X0?Q@0(CK4W;QXQ*N3\FUP2LN3T$L%H]%+=?6KHA%C"=>AR^C M4^\I4-Z$RUOD@%M#5Z5#9H6B75S>4KUE 7L)@7%1 *+XD"C>3_",*,90)T_) MN2*A]@K*,/:6$I"*!..O!*2:T?D*XD6X'E13)7$]A#KTH2S5H:\RZR%0ENK0 MJF;$@&M;)"P]TYNM7,O0,1V!:%J%IDZN35\03?($#?M%T*FNRB;>N"L+XNW8 M>%,UT,1U,U*&!ZU\$Q48'2"85H"IBWTNRP4FR0!TFJ\611+7CW@K&]YTA?=[ M5S70Q/4X,H<(W29FHQ!,1;7"UG#P4BXP20:@T[8297H8;\J"MY82.YY7++59 MX34Q+]+WO'B^,?U)+"^Z=]@1EA @,1_14%H#Y]VI7+@N4%(X9@9^3YSS2>_9'O_^-#&V7NB;<3B:,!I'/:ND? 0G'C)ACZHX8L5T24 >.W;/PD3&7 MQ,\,"74M,O5MSS][8M0G4X"49P4D"H!60H%W%.YF/Y/'^#2$9\##V'#(S)!8 MD<^OXR^BTZD#;.:9F:7GU+P+ M.9YFQ\6_&2(=VV5GJ?$TM+?O,U2;_,O\_63XQ#_BZ/QG[L\RMA-&.$Y=1[I4W"2?"S8#SJ!RX+.IZ9VV>HT>ZW^9>O3 MIV9_H'7[6D,?-#5C\*G9@AO>T3QT+J97-U"Y@OG&NO3J&A'L!(K,_<^T40/% M$O?;+CCJ^'?V!:[G3T \6875M5@9!72)R1PG.?O/$^U$_ :;8*:_5_#BSIZ MDEVS1W+C3>A2TFQ"_9'MQI]'H]!+#\260!QYM*UP#%<#\4ER'"R10Z\?7^R%$#&IYJ-]>=>N.V%4[VB'WC0=Q7.#KWUJMM6 MUD* :"4OAEB19/Q\]5?_^NM???+M\^"U12%*,N+Z\H[<]C]?KMIQH3I<./U> MOZT3BQL\7\2L<+-C0TQ=^ERTZN-\I*^8W(6^*0EYT,X#2\%501O+/3+G@9$O M<&8E[]83"/G1Y"Q>])^TV-'V7NG<4O,2" MS[--MDJ"/\:^Z,<7_%LRB'/)-"1],XRH0P9I?ON&IY<1%25 1;ZBR@- 9C8I M\APT).7JCJ_Z/8BF+Z3JEY*+\P>VIV$R,06/6%42JN:BE!4\'%#?LKUIY$P\ ME_I/%=?G,A2*8(R.LD19'M_RHBQ1EK@G]/QRW!-:NITNWNAM'?=6*Q><#@>A MDLCJN.C'+=$KBOZ"V@.JL,8+VZ\AVHZ--E6C8MS 6LK(6&^T<$=!1%-AW5+R M-1] -*'K3[9X:RK1:!6WLY $;_FV0"TAW"H4:N(6UC+'"(:&'=40386AJ=% M-)4+39(AZ%3/EQPO80R (:<4@.O4=RDB+CG>5 TZ*[R+]5&K?(^V'>S)AY;6 MS)7-VL0&W/L5<7Q0'#?:N?HF(([+B6.IXAWQ:V&->TN)I-L*RC "EQ21#26& M@*]%I)HQ^@KJ_V34#\E?U'FH_ H]7 4B/7TH2W7HJ\PJ$)2E.K2J&3?@BAX) MY_WT+O:N13 5-8F<+\^+8)(G9-CSE)[1R+6\L&P)!,Q@(>#* #A5 TU<)"-E M?-#4&NHC#=50TU<)"-SD-#6 M<%4#@JFH^K].74,PE0E,D@&HKL0#>T7'$% M+BM ')<+QVW$L4(XEBK<$;\6%B/DJT8I6_RS@C),^$J*2*U2B%0S1E]!?=]Z MH*[)+#*P?3-R:.CY3^0VFDX]/ZRFIN(2"W7H0UFJ0U]EEEB@+-6A5 V7+)^"$,L+MZ'!3-L4 ?85PF&.N]7-M((8S+ M"6.IHA?QZWGU=[N9:]E3V:9%5U"&T_*R E+5+BR5B<]7$#^@OF5[#S3@2TS\ M:JHFKD50ASZ4I3KT568M LI2'5K5C!QP78F$4W*&KM<-B9+BB*92HTEK8KE MN= D&8(:"F\=AVA#M!T.;:H&F;BN1,K00.^TL>$?HJFP%?OVE:^C&+K24"'(5"C=Q]8K,<8+1QJU.$$V%H:F'NS"5 M#$V2(>BTH\1&O!AURH(W-4I$*[7/,ZZ0J>#2@G8K7T(+UQ8@CDN%XZZ>*T1& M')<3QU+%.^+70N>+AA(!]PK*, *7%)'8BT7^&'T%]=UVOD*J8N6Q(!LUB(MQ+@3=5 $Y?*2!D>--L8:R*8B@*3@2NRRP4FR0"4 M;ZA20L^/:), ;7I+8;BI&F?B&IGCUGOM.8)HY%+)381BA'%\,)8/; T=UVN5 M"TRR :BMQ![$&*]* K>>$M5\U8I7<7U-Y=8E-(TF]NY '"N X_V,QA#'&.[D MJ7K/UQZV;.'/"L(P_)82C_EVLY84CVK&YRN(_QH"E*NID+@*0QWZ4);JT%>9 M51@H2W5H53-@P!4U$D[TY=\/%;,1B"?$DQ1XD@Q#U^_ZB!_$3T7PHVHPB*M> MT(&C 48\(9[*AR?),"270T?\('XP(,3E*;OX.*5MJZK\&H#A%O9X-9LXV)LZ:)=7-Q2N44!N"0 42P_BO<3/".*,=3)4W*N M2*B]@C*,O:4$I"+!^"L!J69TOH)X$:X'U51)7 ^A#GTH2W7HJ\QZ")2E.K2J M&3'@VA8)2\]:$*OGV6P&TQ&(IA5H:C5P"^]RH4DR!)WJN1H*E"UU@-UB$&\E MP)NJ@2:NFY$R/#",1JX]CS \0#2M0A.V)BP9FB1#T*F1:^PKB?-'O)4-;T:] MJP;<*A1JXHHI.]Y^7QC^I-87G3OL",L(CBRWWXU)\JX>D+\>EY8^D:O:=UF MKM3P1E9(*6!4951E:559USH%+/)#599#EJM=7(] (G_BH+0'C[M2N7 &0F2&Q(I]?QU]$IU,'V,SS,DO/JY<5C 5)ZA\50.,=R#B&$$ KYG(JU\'@7,Y'I],9$J_AW[Z2.FH+9G]SZC/\[H$-YX3IU'^A2<)%\+!H1.X+*@V[\P M>I=]8]#M]UL?+RZZ'[M]_;*EM3O=MC'XU((;WM$\A"YF5S>0N8+[QKKLZAH9 M[(2*S/W/U%$#S1+WVRYXZOAW]@6NYT] /EF-U;58&P5VB@)9=LT=RXTWH4LYL0OV1[<:?1Z/02P_$ID <>;2M< Q7 _%) M;AQ,D4.G 3M/_UB2U.%EOK.-W&&_?GRQ%D/&IEK;^G)[O5*/P)Q[T M9_G"BIS@YZN_^M=?_^J3;Y\'I']]06Z_?[R]NKCJWUQ=5GW# M@#*D%U0?;E9IB'FH8>7<=V@*6JS!U^N+R^O;RPL"?]U^_7QUT;^#'[=W\']? M+J_O;LG73^3J>O#URR4Y(]^O^]\OKN "Q+_2M%;&89]^K]_6B<4C2%]D >!F MQ_;^2MJQHQ.:#N [%9KW0%K5 M-<(H8Y0QREA^!WPHNDOEC%4',])7C()VRM0-<6FNIZ#-[L<^8^0+G!@'Y-*U MF$4NF,GXC"=IZ+6*(Z ,)AK-,IHMI&^+V'@?9GF9%_E6:>W)BAN:WCL:*K;@ M!$*F3)#99964!2H5*M5>E:JWTQX-0P)+ 1*L5+.36E"CT'?'APVW_<]7@MY MQBM?G2BP'Q@_2"<>D/4?&MJ>6Q+R5=+9_;KQ3C=7RR]TXPBF93#UM'J>"28$ MDYQ@*A.M&$W($TU\\STK,D/BLPFS;(P;9#3US5S3$&CI$4NK.H%AY\+J8*E, MM&+4($_4<,L) G>/C"_!'S1>A@NR$;^6+^8E;(6!*B5=+4/<]9 MY^H^A58?L;1J4JR)6*H,ELI$*T80\D00-RP(_<@,XS8B&#A(:NP[]0X:>\12 M0?-@&(56"$QEHA4C!WDBAZO)E-H^GZK@ZRY&GF<]VHY3$EI54M ]#Q,-'"U@W MCV#", +Q)#VM&$;($T;T,]L]/ \D,(20S>KK&DYB()BPD@:Q)#6M&#[($SY\ MMD-[% Z(.%X0D*'O38 ^%XY$_* 7G_9<'+>_3.L^.KP<<;_[4[V9S]:^E@]S M^>Z-$46HQV\(^TK!WNBTZRV$?45A7RFH-SNY%L8KAO2WJZ".N2)Y M@KWMJ. M!6&Z2 ;S1/L9EQS55.6JA97,$E74YRH+6B/75!>"MO*@+1.M& G)$PE]\GP& MS^*-5T1;7K'_B!<")T1N#TMOI)OP.-5SE=[D\B'H)A!Z6>AI]5V:NB/T5(9> MF6A5=6+N\\O3<>2>#<'?DY#^1(!7*F^KM[1<(TO%$K=HUZL%>Z/3RY4%1-BK M /M*0;W9SM5O4S&DX\RJYF5U5+0ZD6Y7LF.JV"V6)LI31]QS*WRA-J )K MBP8>5@/OB[ZR)IEW^?2BTL3U7IXL<:[4&.9Y45=DUI5FO9%GXA1UI22Z@G&? M:H0J$/==K*Y$+@FQ*FGH?MT#MI)&/!4:;FAU#:,-Q%[Y:<5H ^E3@CZL?E2G M^C%?6@N+'U'+48RD1K MJ:*&=(S>K5 >!FE5=^B&,D89HXSE=\"'HGNS,P:B#CR^[6X7T,:7_V,; $M" MTW4TN6=^0";TB;A>2.#M))J2J<],.V#.$[$B1D*/^%XDTN#UDBIQE8RSZ@89 M98FRE-&A[MV)O@OIO<-FQ\6_XA^1T9C_S'RC8[OL+/7TAO;V?<9_F,P-F9_] M"&,[%Y)?K'DJQ.EBL&],;)^J P?H?Q]OW)DOV*3[6T]>?T M?*<:A3_QH"]KONJVE<4;^C&\7_YL[I+IX=>+GX^QWMQ[C@4/Z%O_B@)>T/') M=JEKPDWD"Z-!Q*LY3K_7;^O$XGB%B-=V"3S9B1L@L9\FFX;SO=L(G4# &P:X MN6R)8@FD5?UX&&6,,D89RS\6.D9AZM&)5AW,2%\Q"MHI4\ODI1%LCF*/%8'X MW=AGC'R!$^. 7,)8UR(7S&0\VTP:>JWB""B#B4:SC&8+Z=LB-MZ'65[F1;X5 MU7NRXH:F]XZ&BBTX@9 I$V2Z%3,I-S9\7F_!]'T MA>**I5F9^0/;TY!WG?[M]W?PB%6UOJHN9YQEOV__^)5.IN_[N62Q5]97P X4 M3I^4^^SLC:Y"%B>\T;5.KN4)4LL"E0J5:K]*M5/[73EE@4IUJ!5E[?HN@]'R M[ W\MHHAZ8V(2"\P(BWSR+1\.M_HY/(HZ#003"O U,;U[>4"DVP JC

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end